SYMPOSIUM ON RECENT DEVELOPMENT OF NOVEL METFORMIN-BASED COMPOUNDS AS ANTIDIABETIC TYPE 2 AGENTS!

Date: 13 December 2023 (Wednesday), 

Time: 9:00 am - 12:00 pm (Malaysia Standard Time)

Venue: HOTEL EASTIN

or 

Join Facebook Live:

INTRODUCTION

Diabetes mellitus is one of the most prevalent metabolic and chronic diseases in the world. According to the National Diabetes Institute’s records, Malaysia has the highest rate of diabetes in Asia. There are about 2.5 million adults with diabetes in Malaysia, aged 18 and above. Metformin (dimethylbiguanide) is the current first-line pharmacological treatment for type 2 diabetes (T2D) in almost all guidelines and recommendations worldwide. Metformin decreases hepatic glucose production, decreases intestinal absorption of glucose, and improves insulin sensitivity by increasing peripheral glucose uptake and utilization. However, metformin shows poor oral bioavailability (~50%). It does not undergo metabolism like many other drugs but it is excreted unchanged in the urine. There have been serious concerns about the adverse effects of metformin. It causes lactic acidosis with the symptoms of dizziness, muscle pain, tiredness, difficulty breathing, irregular heartbeat, nausea, etc. To overcome these problems, orally administrable metformin derivatives with enhanced bioavailability are needed. This symposium aims to undertake the development of novel metformin derivatives and to improve the performance of these metformin-based compounds by an advanced formulation.

OBJECTIVE